Get the Stockscreener App
3.9951
4.04%
0.1551
Organogenesis Holdings Inc stock is traded at $3.9951, with a volume of 405.87K.
It is up +4.04% in the last 24 hours and down -30.04% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$3.84
Open:
$3.86
24h Volume:
405.87K
Relative Volume:
0.24
Market Cap:
$507.01M
Revenue:
$433.14M
Net Income/Loss:
$4.95M
P/E Ratio:
111.91
EPS:
0.0357
Net Cash Flow:
$6.55M
1W Performance:
+0.63%
1M Performance:
-30.04%
6M Performance:
-17.12%
1Y Performance:
+14.14%
1-Day Range:
$3.84
$4.10
1-Week Range:
$3.595
$4.10
52-Week Range:
$2.6101
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
3.995 | 487.34M | 433.14M | 4.95M | 6.55M | 0.0357 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Analysis Recap: Is Organogenesis Holdings Inc backed by strong institutional buyingJuly 2025 Final Week & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Macro: Is Organogenesis Holdings Inc a strong growth stockJuly 2025 Action & Accurate Intraday Trade Tips - baoquankhu1.vn
About Us - FinancialContent
The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28% - simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - yourwyominglink.com
Hedge Fund Bets: Is Organogenesis Holdings Inc benefiting from innovation trendsDay Trade & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc.ORGO - FinancialContent
Europe Advanced Wound Care Market Size, Share Projections 2032 - openPR.com
Published on: 2026-01-13 05:15:38 - baoquankhu1.vn
Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth? - Sahm
Organogenesis drops as Medicare to pull skin substitute LCDs (update) - MSN
Is Organogenesis Holdings Inc. (2PQ) stock protected from inflationJuly 2025 Action & Free Technical Pattern Based Buy Signals - Улправда
Is Organogenesis Holdings Inc. stock a buy in volatile markets2025 Top Decliners & Growth Oriented Trade Recommendations - Улправда
What margin trends mean for Organogenesis Holdings Inc. stockIPO Watch & Pattern Based Trade Signal System - Улправда
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis ... - Bluefield Daily Telegraph
PRN_FinancialWrapper - FinancialContent
ORGOOrganogenesis Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Three rising investors just landed bigger roles at a healthcare PE firm - Stock Titan
Organogenesis (NASDAQ:ORGO) Trading Down 5% – Time to Sell? - Defense World
Organogenesis (NASDAQ:ORGO) Shares Down 5%Here's What Happened - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring 64% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Organogenesis Holdings extends leases for Canton facilities through 2032 By Investing.com - Investing.com Australia
Organogenesis Holdings extends leases for Canton facilities through 2032 - Investing.com
Organogenesis Extends Long-Term Leases for Key Facilities - TipRanks
Organogenesis (NASDAQ:ORGO) Shares Gap DownTime to Sell? - MarketBeat
Organogenesis' (ORGO) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision - Investing.com Australia
Organogenesis stock holds Buy rating at BTIG after CMS LCD decision By Investing.com - Investing.com South Africa
Organogenesis stock rises after initiating FDA application for knee arthritis treatment By Investing.com - Investing.com India
Organogenesis Initiates BLA Submission For ReNu In Knee Arthritis - Nasdaq
Organogenesis begins FDA rolling review for knee arthritis treatment By Investing.com - Investing.com Nigeria
Organogenesis starts rolling submission for ReNu allograft for knee arthritis - Seeking Alpha
Organogenesis stock rises after initiating FDA application for knee arthritis treatment - Investing.com Nigeria
Organogenesis begins FDA rolling review for knee arthritis treatment - Investing.com
Organogenesis Announces Initiation of Biologics License Application for ReNu® - The Manila Times
Organogenesis Holdings Inc. Initiates Biologics License Application for ReNu® to Address Knee Osteoarthritis Pain - Quiver Quantitative
Biologic treatment for knee arthritis pain begins FDA license bid - Stock Titan
Gains Recap: Is Organogenesis Holdings Inc stock dividend yield sustainableWeekly Gains Report & Fast Gaining Stock Strategy Reports - moha.gov.vn
Net current asset value per share of Organogenesis Holdings, Inc. Class A – BER:2PQ - TradingView — Track All Markets
BTIG reiterates Organogenesis Holdings (ORGO) buy recommendation - MSN
Is Organogenesis Holdings Inc. stock a bargain at current levels2025 Momentum Check & Advanced Technical Analysis Signals - Улправда
Assenagon Asset Management S.A. Has $20.49 Million Stock Position in Organogenesis $ORGO - MarketBeat
Organogenesis (NASDAQ:ORGO) Shares Down 3.7% on Insider Selling - MarketBeat
Organogenesis Holdings Inc. (ORGO) Stock Analysis: 47% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):